BAIT
BAP1
HUCEP-13, UCHL2, hucep-6
BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)
GO Process (8)
GO Function (5)
GO Component (4)
Gene Ontology Biological Process
- cellular protein modification process [NAS]
- monoubiquitinated histone H2A deubiquitination [IDA]
- monoubiquitinated protein deubiquitination [IDA]
- negative regulation of cell proliferation [TAS]
- protein K48-linked deubiquitination [IMP]
- protein deubiquitination [IDA]
- regulation of cell cycle [IMP]
- regulation of cell growth [IMP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
CREBBP
CBP, KAT3A, RSTS
CREB binding protein
GO Process (21)
GO Function (15)
GO Component (5)
Gene Ontology Biological Process
- N-terminal peptidyl-lysine acetylation [IDA]
- Notch signaling pathway [TAS]
- cellular lipid metabolic process [TAS]
- cellular response to hypoxia [TAS]
- chromatin organization [TAS]
- embryonic digit morphogenesis [TAS]
- gene expression [TAS]
- histone acetylation [IDA]
- homeostatic process [NAS]
- innate immune response [TAS]
- negative regulation of transcription from RNA polymerase II promoter [IDA]
- positive regulation of transcription, DNA-templated [IDA, ISS]
- positive regulation of type I interferon production [TAS]
- protein complex assembly [TAS]
- regulation of smoothened signaling pathway [TAS]
- regulation of transcription from RNA polymerase II promoter in response to hypoxia [TAS]
- regulation of transcription, DNA-templated [IDA, TAS]
- response to hypoxia [TAS]
- signal transduction [NAS]
- small molecule metabolic process [TAS]
- transcription initiation from RNA polymerase II promoter [TAS]
Gene Ontology Molecular Function- MRF binding [IDA]
- RNA polymerase II activating transcription factor binding [TAS]
- RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription [IDA]
- RNA polymerase II transcription coactivator activity [TAS]
- RNA polymerase II transcription factor binding [IPI]
- RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription [IDA]
- acetyltransferase activity [IDA]
- core promoter proximal region sequence-specific DNA binding [IDA]
- histone acetyltransferase activity [IDA]
- p53 binding [IPI]
- protein binding [IPI]
- sequence-specific DNA binding transcription factor activity [TAS]
- signal transducer activity [TAS]
- transcription coactivator activity [IDA, IPI]
- transcription factor binding [IPI]
- MRF binding [IDA]
- RNA polymerase II activating transcription factor binding [TAS]
- RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription [IDA]
- RNA polymerase II transcription coactivator activity [TAS]
- RNA polymerase II transcription factor binding [IPI]
- RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription [IDA]
- acetyltransferase activity [IDA]
- core promoter proximal region sequence-specific DNA binding [IDA]
- histone acetyltransferase activity [IDA]
- p53 binding [IPI]
- protein binding [IPI]
- sequence-specific DNA binding transcription factor activity [TAS]
- signal transducer activity [TAS]
- transcription coactivator activity [IDA, IPI]
- transcription factor binding [IPI]
Gene Ontology Cellular Component
- cytoplasm [IDA]
- nuclear body [IDA]
- nuclear chromatin [IDA]
- nucleoplasm [IDA, TAS]
- nucleus [IC, IDA]
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors.
Exploiting cancer vulnerabilities is critical for the discovery of anticancer drugs. However, tumor suppressors cannot be directly targeted because of their loss of function. To uncover specific vulnerabilities for cells with deficiency in any given tumor suppressor(s), we performed genome-scale CRISPR loss-of-function screens using a panel of isogenic knockout cells we generated for 12 common tumor suppressors. Here, we provide ... [more]
Sci Adv Dec. 13, 2021; 8(19);eabm6638 [Pubmed: 35559673]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507) [viability (PATO:0000169)]
Additional Notes
- CRISPR GI screen
- Cell Line:HEK-293A
- Experimental Setup: Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library: TKO v3 (ADDGENE:90294)
- Significance Threshold: BAGEL (QBF_X_TSG KO>5, QBF_X_WT_Average<3, and QBF_X_TSG KO - QBF_X_WT_Max>5, where X is any gene from TKOv3 library) and DrugZ (P<0.01)
- Significance Threshold: BAGEL (QBF_X_TSG KO>5, QBF_X_WT_Average<3, and QBF_X_TSG KO - QBF_X_WT_Max>5, where X is any gene from TKOv3 library) and DrugZ (P<0.01)
Curated By
- BioGRID